Enzon Pharmaceuticals Company Profile (NASDAQ:ENZN)

About Enzon Pharmaceuticals (NASDAQ:ENZN)

Enzon Pharmaceuticals logoEnzon Pharmaceuticals, Inc. receives royalty revenues from existing licensing arrangements with other companies primarily related to sales of four marketed drug products: PegIntron, Sylatron, Macugen and CIMZIA. The Company has no clinical operations and limited corporate operations. PegIntron is used both as a monotherapy and in combination with REBETOL (ribavirin) capsules for the treatment of chronic hepatitis C. Macugen is used for the treatment of neovascular (wet) age-related macular degeneration. Sylatron is used for the treatment of melanoma. CIMZIA is used for the treatment of moderate to severe rheumatoid arthritis and Crohn's disease. CIMZIA is a biologic medicine that counteracts tumor necrosis factor (or TNF), which promotes inflammation of the joints in rheumatoid arthritis.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:ENZN
  • CUSIP: 29390410
  • Web: enzon.com/
Capitalization:
  • Market Cap: $16.8 million
  • Outstanding Shares: 44,214,000
Average Prices:
  • 50 Day Moving Avg: $0.38
  • 200 Day Moving Avg: $0.31
  • 52 Week Range: $0.22 - $0.50
P/E:
  • Trailing P/E Ratio: 19.00
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $11.03 million
  • Price / Sales: 1.52
  • Book Value: $0.34 per share
  • Price / Book: 1.12
Profitability:
  • Net Margins: 61.77%
  • Return on Equity: 128.45%
  • Return on Assets: 124.59%
Misc:
  • Average Volume: 58,119 shs.
  • Short Ratio: 1.03
 

Frequently Asked Questions for Enzon Pharmaceuticals (NASDAQ:ENZN)

What is Enzon Pharmaceuticals' stock symbol?

Enzon Pharmaceuticals trades on the NASDAQ under the ticker symbol "ENZN."

How were Enzon Pharmaceuticals' earnings last quarter?

Enzon Pharmaceuticals Inc (NASDAQ:ENZN) issued its quarterly earnings results on Wednesday, August, 10th. The company reported $0.02 earnings per share for the quarter. The company had revenue of $2.27 million for the quarter. Enzon Pharmaceuticals had a return on equity of 128.45% and a net margin of 61.77%. View Enzon Pharmaceuticals' Earnings History.

When will Enzon Pharmaceuticals make its next earnings announcement?

Enzon Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, November, 9th 2017. View Earnings Estimates for Enzon Pharmaceuticals.

Who are some of Enzon Pharmaceuticals' key competitors?

Who are Enzon Pharmaceuticals' key executives?

Enzon Pharmaceuticals' management team includes the folowing people:

  • Jonathan N. Christodoro, Chairman of the Board
  • Andrew D. Rackear J.D., Chief Executive Officer, Secretary
  • Richard L. Feinstein, Chief Financial Officer, Vice President - Finance
  • Odysseas D. Kostas M.D., Director
  • Jennifer I. McNealey, Director

How do I buy Enzon Pharmaceuticals stock?

Shares of Enzon Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Enzon Pharmaceuticals' stock price today?

One share of Enzon Pharmaceuticals stock can currently be purchased for approximately $0.38.


MarketBeat Community Rating for Enzon Pharmaceuticals (NASDAQ ENZN)
Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  17 (Vote Outperform)
Underperform Votes:  24 (Vote Underperform)
Total Votes:  41
MarketBeat's community ratings are surveys of what our community members think about Enzon Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Enzon Pharmaceuticals (NASDAQ:ENZN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Enzon Pharmaceuticals (NASDAQ:ENZN)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for Enzon Pharmaceuticals (NASDAQ:ENZN)
Earnings by Quarter for Enzon Pharmaceuticals (NASDAQ:ENZN)
Earnings History by Quarter for Enzon Pharmaceuticals (NASDAQ ENZN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/9/2017        
8/10/2016Q3 2016$0.02$2.27 millionViewN/AView Earnings Details
3/18/2013Q4 2012($0.11)$10.01 million$10.65 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Enzon Pharmaceuticals (NASDAQ:ENZN)
Current Year EPS Consensus Estimate: $0.03 EPS

Dividends

Dividend History by Quarter for Enzon Pharmaceuticals (NASDAQ ENZN)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
12/7/2015special$0.2512/30/201512/14/201512/29/2015
7/7/2015special$0.508/13/20157/21/20158/12/2015
12/9/2014special$0.101/8/20151/12/20151/28/2015
12/9/2013special$0.4512/24/201312/16/201312/23/2013
4/23/2013special$1.605/3/20135/7/20136/4/2013
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Enzon Pharmaceuticals (NASDAQ:ENZN)
Insider Trades by Quarter for Enzon Pharmaceuticals (NASDAQ:ENZN)
Insider Trades by Quarter for Enzon Pharmaceuticals (NASDAQ:ENZN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/28/2016Carl C IcahnMajor ShareholderBuy694,023$0.41$284,549.43View SEC Filing  
9/19/2013Robert LebuhnDirectorSell55,926$1.72$96,192.72View SEC Filing  
8/10/2012Robert LebuhnDirectorSell1,933$6.58$12,719.14View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Enzon Pharmaceuticals (NASDAQ:ENZN)
Latest Headlines for Enzon Pharmaceuticals (NASDAQ:ENZN)
Source:

Social

Chart

Enzon Pharmaceuticals (ENZN) Chart for Monday, September, 25, 2017

This page was last updated on 9/25/2017 by MarketBeat.com Staff